At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-3 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
In Brief
A Phase 3 clinical trial evaluating SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, and 1 other intervention for COPD. Completed, enrolled 653 participants across 44 sites.
Detailed Summary
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014) guidelines.
Study Details
Timeline
Interventions
SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
Placebo twice daily (BID) eFlow Closed System (CS) nebulizer